ABSTRACT
An 18-year-old man was hospitalized with fever, dry cough and dyspnea of acute onset. A chest radiograph and chest CT scan revealed diffuse bilateral infiltrates in peripheral lung zones with a small amount of pleural effusion. Laboratory data showed leukocytosis without eosinophilia and hypoxemia. Analysis of bronchoalveolar lavage fluid disclosed an increased proportion (75.5%) of eosinophils. There was no evidence of bacterial, fungi or parasite infection and no history of medication. A diagnosis of acute eosinophilic pneumonia was made on the basis of the findings and the disease was considered to be associated with cigarette smoking because the quantity of his smoking increased after he had been smoking for a year. A challenge test was performed in which he smoked cigarettes, which elicited fever, coughing and dyspnea again, thus the smoking challenge test was positive. In conclusion, the increased amount of cigarette smoking appears to have induced acute eosinophilic pneumonia.
Subject(s)
Pulmonary Eosinophilia/diagnosis , Pulmonary Eosinophilia/etiology , Smoking/adverse effects , Acute Disease , Adolescent , Bronchial Provocation Tests , Bronchoalveolar Lavage Fluid/cytology , Eosinophils , Humans , Leukocyte Count , MaleABSTRACT
A 41-year-old woman took an EVE-A tablet, which contained ibuprofen, because of pyrexia over 39 degrees C. Due to continued pyrexia, she visited a physician and received cefcapene and acetaminophen under a diagnosis of cold. However, next day, she was admitted to our hospital with severe hypoxemia and pulmonary infiltrates on chest radiograph. Analysis of bronchoalveolar lavage fluid disclosed an increased proportion of 66% eosinophils. All of the lymphocyte stimulation tests for EVE-A tablet, cefcapene and acetaminophen showed positive. After the cessation of these drugs, she was successfully treated with steroids. This case was diagnosed as eosinophilic pneumonia caused by several drugs, and to our knowledge, this is the first report in Japan of ibuprofen (EVE-A tablet)-induced pneumonia.
Subject(s)
Analgesics, Non-Narcotic/adverse effects , Ibuprofen/adverse effects , Pulmonary Eosinophilia/chemically induced , Acetaminophen/adverse effects , Acetaminophen/immunology , Acute Disease , Adult , Analgesics, Non-Narcotic/immunology , Cephalosporins/adverse effects , Cephalosporins/immunology , Humans , Ibuprofen/immunology , Lymphocyte Activation , Male , Methylprednisolone/administration & dosage , Prednisolone/administration & dosage , Pulmonary Eosinophilia/drug therapy , Tablets , Treatment OutcomeABSTRACT
A case of eosinophilic pneumonia due to Nicolase (serrapeptase) after recovery from acute eosinophilic pneumonia is described. A 32-year-old woman was previously admitted to another hospital because of acute onset of dyspnea accompanied by cough and fever. Chest X-ray films revealed diffuse infiltration in both lungs two days after her symptoms occurred. Her bronchoalveolar lavage fluid showed 13% eosinophils and transbronchial lung biopsy specimen also showed many eosinophils infiltrating in the lesions of the bronchial submucosa and alveolar septa. No infectious causes or related drugs were found. Acute eosinophilic pneumonia was diagnosed, and her condition improved gradually without steroid treatment. Because she recovered clinically and radiologically, she was discharged from hospital. Half a month later she was treated with Nicolase because of pharyngitis. She was admitted to the hospital again because of dyspnea, cough and fever three days after commencing to take Nicolase. Chest X-ray films also revealed diffuse infiltration in both lungs with pleural effusion, and her bronchoalveolar lavage fluid showed 37% eosinophils. When the drug lymphocyte stimulation test was performed, it was positive for Nicolase. Therefore drug-induced eosinophilic pneumonia was diagnosed. This is a very rare case of Nicolase (serrapeptase)-induced eosinophilic pneumonia after recovering from acute eosinophilic pneumonia.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Peptide Hydrolases/adverse effects , Pulmonary Eosinophilia/chemically induced , Acute Disease , Adult , Female , Humans , Pharyngitis/drug therapy , RecurrenceSubject(s)
Anti-Infective Agents/pharmacology , Clindamycin/pharmacology , Animals , Anti-Infective Agents/therapeutic use , Anti-Inflammatory Agents , Antifungal Agents/pharmacology , Bacteria/metabolism , Bacteria/pathogenicity , Biofilms/drug effects , Ciprofloxacin/pharmacology , Ciprofloxacin/therapeutic use , Clindamycin/therapeutic use , Cytokines/metabolism , Depression, Chemical , Drug Interactions , GABA Agonists , Humans , Shock, Septic/drug therapy , Virulence Factors/biosynthesisABSTRACT
The effects of rokitamycin (ROK) and levofloxacin (LEVX) were investigated in a murine model of enterohaemorrhagic Escherichia coli (EHEC) infection. After C3H/HeN mice were inoculated intragastrically with E. coli O157:H7, ROK (20mg/kg) or LEVX (1.2 mg/kg) was administered intragastrically. The death rate of the mice was noted and the faeces were collected to determine viable cell counts of EHEC and for Shiga-like toxins (SLTs) assays. After the mice were sacrificed, the kidneys and colons of some of the mice were removed for histopathological examination. The death rate of mice administered ROK (19%) was significantly lower than that of the control and LEVX-treated groups (80, 93%, respectively). Viable cell counts of EHEC in the faeces of the control and ROK-treated groups were 10(7) and 10(6) CFU/g at day 5 after the infection, respectively. LEVX reduced the bacterial count by less than 100 CFU/g at day 5. The level of SLTs in the faeces from the ROK group were lower than the LEVX-treated and control groups at day 5. The histopathological findings in the kidneys treated with LEVX showed necrotic tubular epithelial cells and those in the colon, inflammatory infiltrates. These were not seen in the ROK-treated group. These results suggested that ROK suppressed release of SLTs from the EHEC and could be useful in the treatment of EHEC infection.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Escherichia coli Infections/drug therapy , Escherichia coli Infections/microbiology , Miocamycin/analogs & derivatives , Miocamycin/therapeutic use , Animals , Anti-Infective Agents/therapeutic use , Colony Count, Microbial , Disease Models, Animal , Escherichia coli Infections/pathology , Escherichia coli O157/cytology , Escherichia coli O157/drug effects , Feces/microbiology , Levofloxacin , Male , Mice , Mice, Inbred C3H , Ofloxacin/therapeutic use , Survival AnalysisABSTRACT
We investigated the mechanism by which clindamycin (CLI) modulates cytokine induction after lipopolysaccharide (LPS) stimulation. Although CLI decreased the intracellular expression levels of tumor necrosis factor alpha and interleukin 1beta (IL-1beta) and increased IL-6 expression in macrophages, cytokine mRNA expression levels were similar in CLI-treated and untreated groups. Our findings suggest that CLI modulates cytokine production in LPS-stimulated macrophages.